The U.S. Food and Drug Administration have approved GlaxoSmithKline’s three-in-one inhaler for chronic lung disease, Trelegy Ellipta that just last week won an approval recommendation the European Medicines Agency.
Developed with Theravance Biopharma and Innoviva, the med is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD).
According to GSK, nearly a quarter of COPD patients already use three drugs to control their lung disease, making their offering attractive to those in need of more intensive treatment.
While not indicated for asthma, Trelegy Ellipta combines fluticasone furoate, umeclidinium and vilanterol to help patients with severe COPD.
Read the Reuters report